Disappointing Prostate Cancer Phase III Results for Cabozantinib.

Exelixis, the biotechnology firm developing the metastatic medullary thyroid cancer drug, cabozantinib, in the treatment of a variety of cancers, recently announced disappointing Phase III clinical trial results for the use of cabozantinib in the treatment of metastatic,  hormone-resistant (refractory) prostate cancer. The drug continues to be clinically evaluated in metastatic renal cell and advanced hepatocellular carcinomas.

One thought on “Disappointing Prostate Cancer Phase III Results for Cabozantinib.”

Leave a Reply

Your email address will not be published. Required fields are marked *